ERBB2 and breast carcinoma: According to Dominici et al's study of 109 patients with HER2‐positive breast cancer and axillary metastasis,26 the axillary pCR rate was 74% in patients receiving chemotherapy with trastuzumab, suggesting that our axillary pCR rate corresponding to single HER2 blockade is reliable.